Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 May 15;16(10):2576-89.
doi: 10.1093/emboj/16.10.2576.

Calcineurin is required for virulence of Cryptococcus neoformans

Affiliations

Calcineurin is required for virulence of Cryptococcus neoformans

A Odom et al. EMBO J. .

Abstract

Cyclosporin A (CsA) and FK506 are antimicrobial, immunosuppressive natural products that inhibit signal transduction. In T cells and Saccharomyces cerevisiae, CsA and FK506 bind to the immunophilins cyclophilin A and FKBP12 and the resulting complexes inhibit the Ca2+-regulated protein phosphatase calcineurin. We find that growth of the opportunistic fungal pathogen Cryptococcus neoformans is sensitive to CsA and FK506 at 37 degrees C but not at 24 degrees C, suggesting that CsA and FK506 inhibit a protein required for C. neoformans growth at elevated temperature. Genetic evidence supports a model in which immunophilin-drug complexes inhibit calcineurin to prevent growth at 37 degrees C. The gene encoding the C. neoformans calcineurin A catalytic subunit was cloned and disrupted by homologous recombination. Calcineurin mutant strains are viable but do not survive in vitro conditions that mimic the host environment (elevated temperature, 5% CO2 or alkaline pH) and are no longer pathogenic in an animal model of cryptococcal meningitis. Introduction of the wild-type calcineurin A gene complemented these growth defects and restored virulence. Our findings demonstrate that calcineurin is required for C. neoformans virulence and may define signal transduction elements required for fungal pathogenesis that could be targets for therapeutic intervention.

PubMed Disclaimer

References

    1. Science. 1985 Jun 21;228(4706):1443-6 - PubMed
    1. Microbiology. 1996 Apr;142 ( Pt 4):937-43 - PubMed
    1. J Bacteriol. 1986 Jun;166(3):924-9 - PubMed
    1. J Clin Invest. 1986 Dec;78(6):1638-47 - PubMed
    1. Infect Immun. 1988 Jan;56(1):225-9 - PubMed

Publication types

MeSH terms

Associated data